Skip to main content
. Author manuscript; available in PMC: 2018 Aug 1.
Published in final edited form as: Mayo Clin Proc. 2017 Aug;92(8):1291–1303. doi: 10.1016/j.mayocp.2017.04.016

Figure 3.

Figure 3

[18F] AV-1451 tau-PET shows minimal uptake in a normal control patient (top row), mild-moderate uptake in the dentate nucleus of the cerebellum, midbrain and basal ganglia in a patient with progressive supranuclear palsy (PSP), a primary 4R tauopathy (2nd row), and striking uptake in the cortex in a patient with typical Alzheimer’s disease (AD), a 3R + 4R tauopathy, for comparison (bottom row).